Skip to content
Screener

Glaukos GKOS Total Revenue

Total Revenue at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$25.31B+6.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$4.29B+16.7%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$23.39M+19.5%
AbbVie logo
AbbVieABBV
$16.99B+10.2%
Bausch + Lomb logo
Bausch + LombBLCO
$1.39B+9.1%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$10.79M+0.8%

Segments

By product

See full
Glaucoma$155.18M+49.9%
Corneal Health$30.43M+47.8%

By segment

See full
Development And Commercialization Of Ophthalmic Therapies$185.61M+49.5%

By geography

See full
US$146.74M

Other financials

Income statement

See full
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.2%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Net sales$185,610$124,120$336,181$230,784
Cost of sales34,01626,89667,35551,212
Gross profit151,59497,224268,826179,572
Operating expenses:
Selling, general and administrative116,06083,375209,003154,048
Research and development51,30136,53895,44668,891
Acquired in-process research and development1,500-1,500-
Total operating expenses168,861119,913305,949222,939

Item 1. Financial Statements

FAQ

What is Glaukos's total revenue?
Glaukos (GKOS) reported total revenue of $185.61M in Q2 2026.
How has Glaukos's total revenue changed year-over-year?
Glaukos's total revenue increased by 49.5% year-over-year, from $124.12M to $185.61M.
What is the long-term trend for Glaukos's total revenue?
Over 4 years (2021 to 2025), Glaukos's total revenue has grown at a 14.6% compound annual growth rate (CAGR), from $294.01M to $507.44M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Glaukos's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude